Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
| ▸ | KDR | P35968 | 2/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.82 |
| ▸ | HTT | P42858 | 2/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.82 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | RAF1 | P04049 | 6/20 | 0.62 |
| ▸ | BRAF | P15056 | 6/20 | 0.62 |
| ▸ | SCD | O00767 | 1/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.57 |
| ▸ | TUBB | P07437 | 3/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mebendazole SCHEMBL3429179 | 1.00 | ABL1 (0.82) | ABL1LMNACYP1A2ALDH1A1KDR | |
| Mebendazole SCHEMBL15860 | 1.00 | ABL1 (0.82) | ABL1LMNACYP1A2ALDH1A1KDR | |
| Mebendazole SCHEMBL21051203 | 0.99 | ABL1 (0.80) | ABL1LMNACYP1A2ALDH1A1KDR | |
| Mebendazole SCHEMBL17262440 | 0.99 | ABL1 (0.80) | ABL1LMNACYP1A2ALDH1A1KDR | |
| Mebendazole SCHEMBL21051200 | 0.99 | ABL1 (0.80) | ABL1LMNACYP1A2ALDH1A1KDR | |
| Mebendazole SCHEMBL27690766 | 0.99 | ABL1 (0.80) | ABL1LMNACYP1A2ALDH1A1KDR | |
| Mebendazole SCHEMBL28186589 | 0.99 | ABL1 (0.80) | ABL1LMNACYP1A2ALDH1A1KDR | |
| Mebendazole SCHEMBL28588780 | 0.98 | ABL1 (0.78) | ABL1LMNACYP1A2ALDH1A1KDR | |
| Mebendazole SCHEMBL21051204 | 0.95 | ABL1 (0.75) | ABL1LMNACYP1A2ALDH1A1KDR | |
| Mebendazole SCHEMBL28858902 | 0.95 | ABL1 (0.75) | ABL1LMNACYP1A2ALDH1A1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| EP-4101438-B1 | COMBINATION TREATMENT OF A SAPONIN AGENT AND AN ANTHELMINITIC AGENT AGAINST CANCER | RAINCASTLE BIO LTD (GB) | 2025-04-16 | — | — | EP | claimed |
| EP-4048284-B1 | METHOD FOR TREATING CANCERS | ACURA NANOMEDICINE CORP (TW) | 2025-03-19 | — | — | EP | claimed |
| EP-4140504-B1 | MICELLE MADE FROM BENZIMIDAZOLE-CARBOHYDRATE CONJUGATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTICANCER AGENT OR ANTIVIRAL AGENT COMPRISING THE SAME | BIOMETRIX TECH INC (KR) | 2025-01-15 | — | — | EP | claimed |
| EP-3907230-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT COMPRISING THE SAME | BIOMETRIX TECH INC (KR) | 2024-08-28 | — | — | EP | claimed |
| US-20240245743-A1 | USE OF CINNAMOMUM ZEYLANICUM ESSENTIAL OIL (EO) AS HUMAN MELANOMA CELLS DEATH INDUCER AND AS POSSIBLE ADJUVANT IN PHARMACOLOGICAL THERAPIES | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2024-07-25 | — | — | US | claimed |
| EP-3968964-B1 | METHOD FOR PRODUCING NANOPARTICLES | LEON NANODRUGS GMBH (DE) | 2024-07-10 | — | — | EP | claimed |
| EP-4337239-A1 | USE OF CINNAMOMUM ZEYLANICUM ESSENTIAL OIL (EO) AS HUMAN MELANOMA CELLS DEATH INDUCER AND AS POSSIBLE ADJUVANT IN PHARMACOLOGICAL THERAPIES | Consiglio Nazionale delle Ricerche (IT) | 2024-03-20 | — | — | EP | claimed |
| EP-3843705-B1 | PREPARATION OF NANOSUSPENSION COMPRISING NANOCRYSTALS OF ACTIVE PHARMACEUTICAL INGREDIENTS WITH LITTLE OR NO STABILIZING AGENTS | CENTRE NAT RECH SCIENT (FR) | 2023-11-29 | — | — | EP | claimed |
| EP-2916820-B1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL TECH LLC (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3836905-B1 | NOVEL ORAL COMPOSITION | APILLET APS (DK) | 2023-10-04 | — | — | EP | claimed |
| EP-3641747-B1 | PAR-4 SECRETAGOGUES FOR THE TREATMENT OF CANCER | CIPLA LTD (IN) | 2023-09-06 | — | — | EP | claimed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| WO-2022238831-A1 | USE OF CINNAMOMUM ZEYLANICUM ESSENTIAL OIL (EO) AS HUMAN MELANOMA CELLS DEATH INDUCER AND AS POSSIBLE ADJUVANT IN PHARMACOLOGICAL THERAPIES | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2022-11-17 | — | — | WO | claimed |
| US-20220241368-A1 | PERCUTANEOUS ANTI-MICROBIOTA FORMULATIONS | HOFFMAN TECHNOLOGIES LLC | 2022-08-04 | — | — | US | claimed |
| CN-114828860-A | Transdermal microflora preparation | 霍夫曼技术有限责任公司 | 2022-07-29 | — | — | CN | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3599855-B1 | DELAYED RELEASE FEED-THROUGH VETERINARY COMPOSITIONS WITH OVICIDAL AND LARVICIDAL ACTIVITY AGAINST SUSCEPTIBLE AND RESISTANT STRAINS OF PARASITES IN RUMINANTS' FECES, USE OF THESE COMPOSITIONS, METHOD FOR DELAYING THE RELEASE OF THESE COMPOSITIONS | Champion USA LLC (US) | 2022-03-02 | — | — | EP | claimed |
| EP-4285998-B1 | GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY | UNIV NOTTINGHAM (GB) | 2026-05-06 | — | — | EP | disclosed |
| US-20260103488-A1 | ACTIVATING AGENTS | INTERK PEPTIDE THERAPEUTICS LIMITED (AU) | 2026-04-16 | — | — | US | disclosed |
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| US-20250255894-A1 | INHIBITORS OF EIF4A | Aceae Nutra Limited (GB) | 2025-08-14 | — | — | US | disclosed |
| US-20250241898-A1 | Topical Benzimidazole Formulations and Methods for Use in Treating Inflammatory Dermatoses | JJR&D, LLC | 2025-07-31 | — | — | US | disclosed |
| US-12357696-B2 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| US-12324861-B2 | Beaded nonwoven membrane as a drug delivery system | CEBIOTEX, S.L. (ES) | 2025-06-10 | — | — | US | disclosed |
| US-20250134827-A1 | BEADED NONWOVEN MEMBRANE AS A DRUG DELIVERY SYSTEM | CEBIOTEX, S.L. (ES) | 2025-05-01 | — | — | US | disclosed |
| EP-4543441-A2 | TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES | JJR&D, LLC (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4101438-B1 | COMBINATION TREATMENT OF A SAPONIN AGENT AND AN ANTHELMINITIC AGENT AGAINST CANCER | RAINCASTLE BIO LTD (GB) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025073982-A1 | METHOD OF INTRACELLULAR PEPTIDE LIGATION | THE UNIVERSITY OF BATH (GB) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025075711-A1 | METHODS AND MATERIALS FOR TREATING HYPEROXALEMIA AND/OR HYPEROXALURIA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-3253757-B1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20250049032-A1 | ETHYLENE SIGNALING ACTIVATOR MODULATES ROOT SYSTEM ARCHITECTURE | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2025-02-13 | — | — | US | disclosed |
| US-20250019397-A1 | Peptide Activating Agent | INTERK PEPTIDE THERAPEUTICS LIMITED (AU) | 2025-01-16 | — | — | US | disclosed |
| EP-4489763-A1 | INHIBITORS OF EIF4A | Aceae Nutra Limited (GB) | 2025-01-15 | — | — | EP | disclosed |
| US-20240423959-A1 | TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES | JJR&D, LLC | 2024-12-26 | — | — | US | disclosed |
| US-12134663-B2 | Cationic peptides for activating Lck | INTERK PEPTIDE THERAPEUTICS LIMITED (AU) | 2024-11-05 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024175824-A1 | PROBES, USES AND METHODS FOR THE DIAGNOSIS, MONITORING AND ASSESSMENT OF TREATMENTS FOR FILARIASIS | INSTITUTO DE SALUD CARLOS III (ES) | 2024-08-29 | — | — | WO | disclosed |
| CN-114848178-B | Preparation method of 3D printing shape memory dental model and preparation method of invisible appliance | 兰州市口腔医院 | 2024-08-20 | — | — | CN | disclosed |
| US-20240115552-A1 | MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS | THE JOHNS HOPKINS UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| EP-3931192-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337661-A1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED HETEROCYCLE DERIVATIVES AS PEST CONTROL AGENTS | Bayer Aktiengesellschaft (DE) | 2024-03-20 | — | — | EP | disclosed |
| EP-3814346-B1 | HETEROCYCLIC DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2024-03-20 | — | — | EP | disclosed |
| US-11912789-B2 | Peptide activating agent | INTERK PEPTIDE THERAPEUTICS LIMITED (AU) | 2024-02-27 | — | — | US | disclosed |
| EP-4298908-A2 | TRICYCLIC CARBOXAMIDES FOR THE CONTROL OF ARTHROPODS | Bayer Animal Health GmbH (DE) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023249992-A2 | TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES | JJR&D, LLC (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11839684-B2 | Mucoadhesive pharmaceutical composition and preparation method therefor | SAMYANG HOLDINGS CORPORATION (KR) | 2023-12-12 | — | — | US | disclosed |
| EP-4285998-A2 | GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY | The University of Nottingham (GB) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023205802-A2 | SENOLYTIC TARGETS OF SENESCENT CELLS | SENS RESEARCH FOUNDATION (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3601279-B1 | TRICYCLIC CARBOXAMIDES AS CONTROL AGENT FOR ARTHROPODS | BAYER ANIMAL HEALTH GMBH (DE) | 2023-10-18 | — | — | EP | disclosed |
| CN-111208283-B | Synergistic tumor inhibiting composition and application thereof | 中国科学院分子细胞科学卓越创新中心 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023170413-A1 | INHIBITORS OF EIF4A | Aceae Nutra Limited (GB) | 2023-09-14 | — | — | WO | disclosed |
| EP-3923936-B1 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR | ZEPHAPHARM LTD (GB) | 2023-08-09 | — | — | EP | disclosed |
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3129057-B1 | GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY | UNIV NOTTINGHAM (GB) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023115042-A1 | ETHYLENE SIGNALING ACTIVATOR MODULATES ROOT SYSTEM ARCHITECTURE | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-4175961-A1 | HETEROCYCLENE DERIVATIVES AS PEST CONTROL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | disclosed |
| US-20230072164-A1 | GRANULAR PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION FROM A PRE-FILLED STRAW AND METHOD OF MANUFACTURING SUCH PHARMACEUTICAL PRODUCT | ALTERNO LABS D.O.O. (SI) | 2023-03-09 | — | — | US | disclosed |
| EP-4144739-A1 | ANELLATED PYRAZOLES AS PARASITICIDES | Bayer Aktiengesellschaft (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-4139304-A1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED HETEROCYCLIC DERIVATIVES AS PEST CONTROL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | disclosed |
| EP-4101438-A1 | COMBINATION TREATMENT OF A SAPONIN AGENT AND AN ANTHELMINITIC AGENT AGAINST CANCER | RainCastle bio. Limited (GB) | 2022-12-14 | — | — | EP | disclosed |
| EP-3497102-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2022-12-07 | — | — | EP | disclosed |
| EP-4096642-A1 | GRANULAR PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION FROM A PRE-FILLED STRAW AND METHOD OF MANUFACTURING SUCH PHARMACEUTICAL PRODUCT | Alterno Labs d.o.o. (SI) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022238391-A1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED HETEROCYCLE DERIVATIVES AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-11-17 | — | — | WO | disclosed |
| EP-3829549-B1 | BEADED NONWOVEN MEMBRANE AS A DRUG DELIVERY SYSTEM | CEBIOTEX S L (ES) | 2022-10-12 | — | — | EP | disclosed |
| EP-3672966-B1 | HETEROCYCLENE DERIVATES AS PESTICIDES | BAYER AG (DE) | 2022-09-21 | — | — | EP | disclosed |
| EP-4055010-A1 | SUBSTITUTED SULFONYL AMIDES FOR CONTROLLING ANIMAL PESTS | Bayer Aktiengesellschaft (DE) | 2022-09-14 | — | — | EP | disclosed |
| US-20220241368-A1 | PERCUTANEOUS ANTI-MICROBIOTA FORMULATIONS | HOFFMAN TECHNOLOGIES LLC | 2022-08-04 | — | — | US | disclosed |
| EP-4036083-A1 | 5-OXY SUBSTITUTED HETEROCYCLES AS PESTICIDES | Bayer Aktiengesellschaft (DE) | 2022-08-03 | — | — | EP | disclosed |
| CN-114828860-A | Transdermal microflora preparation | 霍夫曼技术有限责任公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114814013-A | Method for rapidly screening unknown chemical hazard residues in aquatic products based on high-resolution mass spectrum database | 中国海洋大学 | 2022-07-29 | — | — | CN | disclosed |
| EP-4003966-A1 | 5-AMINO SUBSTITUTED PYRAZOLES AND TRIAZOLES AS PEST CONTROL AGENTS | Bayer Aktiengesellschaft (DE) | 2022-06-01 | — | — | EP | disclosed |
| EP-3765466-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3765465-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2022-05-25 | — | — | EP | disclosed |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| CN-216396286-U | N-methyl-2, 3-diamino-5 chloro-4 bromobenzamide synthesis reduction unit temperature control quantitative feeding reaction device | 德兴市宏达塑胶科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3615540-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3974414-A1 | 5-AMINO SUBSTITUTED PYRAZOLES AND TRIAZOLES AS PESTICIDES | Bayer AG (DE) | 2022-03-30 | — | — | EP | disclosed |
| CN-108536750-B | Image feature binary coding representation method based on point-to-point relation learning and reconstruction | 南京大学 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022053453-A1 | AZOLE CARBOXAMIDE AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-17 | — | — | WO | disclosed |
| US-11248016-B2 | Glycolipids and pharmaceutical compositions thereof for use in therapy | THE UNIVERSITY OF NOTTINGHAM (GB) | 2022-02-15 | — | — | US | disclosed |
| US-11248016-B2 | Glycolipids and pharmaceutical compositions thereof for use in therapy | THE UNIVERSITY OF NOTTINGHAM (GB) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049032-A1 | ETHYLENE SIGNALING ACTIVATOR MODULATES ROOT SYSTEM ARCHITECTURE | GRK6, DGKK, RGS4 | ABL1 2814/4885LMNA 4757/4885CYP1A2 4420/4885 |
| US-12324861-B2 | Beaded nonwoven membrane as a drug delivery system | MFAP1, WDR26, ATP6V0C | ABL1 3846/4885LMNA 1599/4885CYP1A2 3603/4885 |
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | CYP3A43, CYP3A4, CYP4B1 | ABL1 4392/4885LMNA 3133/4885CYP1A2 18/4885 |
| US-20250019397-A1 | Peptide Activating Agent | LCK, CD69, VIP | ABL1 646/4885LMNA 4008/4885CYP1A2 4884/4885 |
| US-12134663-B2 | Cationic peptides for activating Lck | LCK, CD69, NFATC1 | ABL1 558/4885LMNA 3437/4885CYP1A2 4885/4885 |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | RXFP3, AVPR2, RXFP1 | ABL1 2587/4885LMNA 1418/4885CYP1A2 66/4885 |
| US-11248016-B2 | Glycolipids and pharmaceutical compositions thereof for use in therapy | CPT1B, HTT, ACAT1 | ABL1 3177/4885LMNA 3126/4885CYP1A2 4341/4885 |
| US-12357696-B2 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | SI, PIM1, PIM3 | ABL1 3019/4885LMNA 766/4885CYP1A2 389/4885 |
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | SI, PIM1, PIM3 | ABL1 3019/4885LMNA 766/4885CYP1A2 389/4885 |
| US-20250134827-A1 | BEADED NONWOVEN MEMBRANE AS A DRUG DELIVERY SYSTEM | MFAP1, WDR26, ATP6V0C | ABL1 3846/4885LMNA 1599/4885CYP1A2 3603/4885 |
| US-11912789-B2 | Peptide activating agent | LCK, CD69, VIP | ABL1 646/4885LMNA 4008/4885CYP1A2 4884/4885 |
| US-20260103488-A1 | ACTIVATING AGENTS | LCK, LTK, CD14 | ABL1 509/4885LMNA 4570/4885CYP1A2 4013/4885 |
| US-20250255894-A1 | INHIBITORS OF EIF4A | EIF4A1, EIF4EBP1, EIF4E | ABL1 2431/4885LMNA 2166/4885CYP1A2 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.